These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30842342)

  • 1. Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet.
    Ryu JS; Lim JH; Kim HJ; Kim MJ; Park MH; Kim JS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
    Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
    J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
    Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
    Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
    Karachaliou N; Bracht JWP; Fernandez Bruno M; Drozdowskyj A; Gimenez Capitan A; Moran T; Carcereny E; Cobo M; Domine M; Chaib I; Ramirez JL; Camps C; Provencio M; Vergnenegre A; Lopez-Vivanco G; Majem M; Massuti B; Rosell R
    J Thorac Oncol; 2019 Feb; 14(2):304-310. PubMed ID: 30472259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
    Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
    Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
    Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
    Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.
    Zhang T; Rong N; Chen J; Zou C; Jing H; Zhu X; Zhang W
    PLoS One; 2013; 8(11):e79162. PubMed ID: 24223900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
    BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
    Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
    Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
    Zou HZ; Zhao YQ
    Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
    Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
    J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.